




Joint BBS and EFSPi Seminar on  
**Health Technology Assessment**

Allschwil (Basel), June 4, 2013



**Program (16. May 2013)**

**8:30 – 9:00 Registration**

**9:00 – 12:30 Morning session**

**09:00 – 9:05 Welcome**

Mike Branson (Novartis, Switzerland & BBS President)

Session chair: Fred Sorenson (Xcenda)

**09:05 – 09:20** Fred Sorenson (Xcenda, Switzerland)

***Health Technology Assessment – Why is it so important?***

**09:20 – 10:00** Matthias Egger (Univ. of Bern, Switzerland) and Mike Chambers (GSK, UK)

***Moving HTA forward: The Challenges of Incorporating Real World Evidence into Health Technology Assessment***

**10:00 – 10:30** Claudia Nicolay (Lilly, Germany)

***Health Technology Assessment - What's in for Stats?***

**10:30 – 10:45** Coffee break

Session chair: (Chrissie Fletcher, Amgen) representing EFSPi & PSI HTA SIG

**10:45 – 11:15** Jens Gröger (Roche, Switzerland)

***HTA and personalized healthcare***

**11:15 – 11:45** Claire Watkins (AstraZeneca, UK)

***Adjusting overall survival for treatment switch/crossover –  
Recommendations of a cross-institutional statistical working  
group***

**11:45 – 12:15** Skip Olson (Novartis, Switzerland)

***HTA - Use of observational, retrospective or prospective  
studies***

**12:15 – 12:30** Extra time for questions to morning speakers / open discussion before lunch

**12:30 – 13:30** Lunch break

**13:30 – 17:00 Afternoon session**

Chair: Marisa Bacchi (Actelion) representing BBS

**13:30 – 14:00** Bruno Falissard (Univ. of S. Paris & INSERM, France)

***The place of subjectivity in the French system (HAS): a good thing or an archaism?***

**14:00 – 14:30** Ralf Bender (IQWiG, Germany)

***Biometrical topics of Health Technology Assessment in Germany***

**14:30 – 15:00** Friedhelm Leverkus (Pfizer, Germany)

***30 Months AMNOG Health Technology Assessment: Outcomes and Issues***

**15:00 – 15:15** Coffee break

Session chair: Egbert Biesheuvel (MSD, Netherlands & EFSPi Chair, Scientific Committee)

**15:15 – 15:45** Lou Garrison (Univ. of Washington, USA)

***HTA in Emerging Markets: A Framework and Examples***

**15:45 – 16:15** Richard Nixon (Novartis, Switzerland)

***Using early health economic models to support drug development decisions***

**16:15 – 16:45** Chrissie Fletcher (Amgen, UK)

***Using indirect treatment comparisons to support an HTA***

16:45 – 17:25 Panel Discussion: ***Implications of healthcare reform on HTA in the United States***

Tommy Bramley, Senior VP and head of scientific consulting (Xcenda, USA)

John Doyle, Senior VP and head of consulting (Quintiles, USA)

Lou Garrison, Prof. Depts. of Pharmacy, Global Health and Health Services (Univ. of Washington, USA)

Ansgar Hebborn, Head, Global Payer & HTA Program Policy (Roche, Switzerland)

Skip Olson, Global Head HE&OR, Neuroscience and Ophthalmology (Novartis, Switzerland)

Moderators: François Aubin (Past EFSPi President and Head of Biometry, Cardinal Systems, France) and Fred Sorenson (Xcenda, Switzerland)

**17:25 Concluding remarks** Uli Burger (Roche, Switzerland)

**17:30 Adjourn**